Clinical Trial Update: A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating KarXT for acutely psychotic schizophrenia in Chinese adults has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2025-11-21